Takashi Sasaki et al.
Anticancer research, 33(6), 2619-2622 (2013-06-12)
To evaluate the treatment outcomes of irinotecan monotherapy for patients with advanced biliary tract cancer refractory to gemcitabine, cisplatin, and oral fluoropyrimidine. Irinotecan (100 mg/m(2)) was administered intravenously on days 1, 8, and 15, repeated every four weeks. Thirteen patients